NEWARK, Del., July 29, 2022 /PRNewswire/ — ILC Dover LP (“ILC Dover” or the “Company”), specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced the launch of Water for Injection (WFI) for the biotherapeutics market. With this launch, ILC Dover expands its offering of integrated solutions for the entire biotherapeutic and pharmaceutical manufacturing process. They are used in the preparation of media, buffers, and other ingredients for biopharmaceuticals and medical devices.
WFI’s addition follows new product offerings, including single-use fluid bags, as well as the company’s recent acquisition of KSE Scientific in December 2021. As a leading provider of WFI and related solutions to the emerging biopharma, cell and gene therapy, tissue banking and medical device markets, KSE Scientific combines decades of experience in developing world-class products with ILC Dover to create synergies in fluid processing and transfer workflows and to meet customers’ most demanding specifications and end-use applications.
The company will Durham, NCproduce multi-compendium WFI solutions, but will ultimately leverage its growing cGMP acreage to support its customers and partners worldwide.
“When we identify limitations in the markets we serve, we react. By securing supply and strengthening our reliability as a solution provider, ILC Dover is now able to offer WFI and single-use fluid bags to customers around the world.” Corey Walker, CEO of ILC Dover. “As we continue to grow and meet demand, we will remain focused on providing broader and more integrated workflow solutions for the biopharmaceutical, cell and gene therapy and related life sciences end markets.”
In addition, the Company has an expansion project within KSE Scientific’s 25,000 square foot manufacturing facility in Durham, NC, to offer distilled WFI, a key raw material for the biopharmaceutical and cell and gene therapy markets. This expansion allows ILC Dover greater flexibility to serve customers around the world by adding distillation for WFI to existing reverse osmosis capabilities. The proprietary ability to produce WFI through distillation was a key milestone in ILC Dover’s rapid expansion into other sterile liquid offerings to come.
ILC Dover strives to provide comprehensive solutions tailored to the unique needs of its clients. With the recent launch of in-house manufactured fluid bags, fluid transfer assemblies and WFI, ILC Dover can now offer custom WFI solutions with a stable supply chain, unparalleled lead times and rapid scalability.
To learn more regarding ILC Dover’s WFI and cGMP chemistry solutions, please visit https://www.ilcdover.com/products/water-for-injection-wfi-quality-water/ or contact your local sales representative.
